Shocking Truth About Big Pharma and Exorbitant Drug Prices [VIDEO]

June 4, 2023

Shocking Truth About Big Pharma and Exorbitant Drug Prices [VIDEO]

In a video by Patrick from Valuetainment, the issue of high drug prices and the impact of pharmaceutical patents in the United States is explored. Patrick highlights the alarming number of Americans who face bankruptcy due to medical bills they cannot afford. He delves into the patent laws in America, which protect drugs for up to 20 years or even longer, and reveals how pharmaceutical companies extend their patents through various tactics.

Patrick provides examples of drugs whose patents have expired, leading to a significant drop in prices and increased competition in the market. He emphasizes the financial implications of these price reductions on pharmaceutical companies and the potential benefits for consumers. The video also presents a list of the top 10 most expensive drugs in America, shedding light on their exorbitant costs.

Both sides of the argument regarding long patent durations are presented by Patrick. Supporters of longer patents argue that they incentivize innovation, promote drug access, and protect intellectual property rights. However, opponents assert that long patents contribute to high drug prices, monopolistic practices, limited innovation, and ethical concerns.

Patrick proposes a solution in which a patent holder can sell their patent rights to other companies after five years, allowing them to set their own prices for the drug. The original patent holder would receive a 10% share of the sales for the following 15 years. This approach aims to foster competition, reduce drug prices, and still provide financial incentives for innovators.

Throughout the video, Patrick emphasizes the importance of raising awareness about the issue and encourages viewers to participate in discussions and propose alternative solutions. He also highlights the influence of lobbying and mainstream media, which are often funded by pharmaceutical companies and may limit the discourse surrounding drug pricing reforms.

 

You May Also Like…